Toripalimab combined with anlotinib for recurrent extensive‑stage small‑cell lung cancer: A case report

Wu,Ying; Chen,Yinqiao; Yang,Zhouliang

doi:10.3892/etm.2023.12012

Toripalimab combined with anlotinib for recurrent extensive‑stage small‑cell lung cancer: A case report

Authors:
- Ying Wu
- Yinqiao Chen
- Zhouliang Yang
View Affiliations

Affiliations: Department of Oncology, The First People's Hospital of Yongkang City, Yongkang, Zhejiang 321300, P.R. China, Department of Pathology, The First People's Hospital of Yongkang City, Yongkang, Zhejiang 321300, P.R. China
Published online on: May 12, 2023 https://doi.org/10.3892/etm.2023.12012
Article Number: 313
Copyright: © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The 5‑year survival rate of patients with extensive‑stage small cell lung cancer (ES‑SCLC) is <8%; therefore there is an urgent need for more effective treatment. Although immune checkpoint inhibitors have been widely used to treat lung cancer, the efficacy of anti‑programmed death 1 therapy for SCLC is limited due to the abnormal vascular state of the tumour microenvironment. A 66‑year‑old man who was diagnosed with ES‑SCLC and performance status (PS) 3 received first‑line chemotherapy but experienced recurrence. Repeated stage IV thrombocytopenia hindered completion of second‑line chemotherapy. Therefore, the patient was treated with a combination of toripalimab and anlotinib. After two cycles, the patient showed a partial response to therapy; a long‑lasting curative benefit extending 20 months was achieved with PS 1. This novel and effective combined immune/anti‑angiogenic therapy paradigm for patients with relapsed ES‑SCLC and poor PS requires prospective clinical trials.

View Figures

View References

1	Deneka AY, Boumber Y, Beck T and Golemis EA: Tumor-Targeted Drug Conjugates as an Emerging Novel Therapeutic Approach in Small Cell Lung Cancer (SCLC). Cancers (Basel). 11(1297)2019.PubMed/NCBI View Article : Google Scholar
2	Liu L, Zhang X, Zhou L, Yang T, Qiao Y and Jiang X: Carrelizumab combined with anlotinib in the treatment of extensive-stage small cell lung cancer: A case report. Medicine (Baltimore). 100(e27138)2021.PubMed/NCBI View Article : Google Scholar
3	Barrows ED, Blackburn MJ and Liu SV: Evolving role of immunotherapy in small cell lung cancer. Semin Cancer Biol. 86(Pt 3):868–874. 2022.PubMed/NCBI View Article : Google Scholar
4	Ando K, Manabe R, Kishino Y, Kusumoto S, Yamaoka T, Tanaka A, Ohmori T, Ohnishi T and Sagara H: Comparative Efficacy and Safety of Immunotherapeutic Regimens with PD-1/PD-L1 Inhibitors for Previously Untreated Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis. Curr Oncol. 28:1094–1113. 2021.PubMed/NCBI View Article : Google Scholar
5	He Y and An T: Toripalimab in an advanced non-small cell lung cancer patient with poor general condition after multiline treatment: A case report. J Int Med Res. 49(3000605211042988)2021.PubMed/NCBI View Article : Google Scholar
6	Moya-Horno I, Viteri S, Karachaliou N and Rosell R: Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC). Ther Adv Med Oncol. 10(1758834017745012)2018.PubMed/NCBI View Article : Google Scholar
7	Tian Y, Zhai X, Han A, Zhu H and Yu J: Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer. J Hematol Oncol. 12(67)2019.PubMed/NCBI View Article : Google Scholar
8	Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H and Riley D: CARE Group. The CARE guidelines: Consensus-based clinical case reporting guideline development. Headache. 53:1541–1547. 2013.PubMed/NCBI View Article : Google Scholar
9	Amin MB: American Joint Committee on Cancer and American Cancer Society AJCC cancer staging manual. 8th edition. Springer, Chicago IL, 2017.
10	Dall'Olio FG, Maggio I, Massucci M, Mollica V, Fragomeno B and Ardizzoni A: ECOG performance status ≥2 as a prognostic factor in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors-a systematic review and meta-analysis of real world data. Lung Cancer. 145:95–104. 2020.PubMed/NCBI View Article : Google Scholar
11	U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institue: Common Terminology Criteria for Adverse Events (CTCAE)[J/OL]. http://evs.nci.nih.gov/ftp1/CTCAE/About.html.
12	Rossi A, Di Maio M, Chiodini P, Rudd RM, Okamoto H, Skarlos DV, Früh M, Qian W, Tamura T, Samantas E, et al: Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: The COCIS meta-analysis of individual patient data. J Clin Oncol. 30:1692–1698. 2012.PubMed/NCBI View Article : Google Scholar
13	Antonia SJ, Lopez-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, Jäger D, Pietanza MC, Le DT, de Braud F, et al: Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): A multicentre, open-label, phase 1/2 trial. Lancet Oncol. 17:883–895. 2016.PubMed/NCBI View Article : Google Scholar
14	Ott PA, Elez E, Hiret S, Kim DW, Morosky A, Saraf S, Piperdi B and Mehnert JM: Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study. J Clin Oncol. 35:3823–3829. 2017.PubMed/NCBI View Article : Google Scholar
15	Chung HC, Piha-Paul SA, Lopez-Martin J, Schellens JHM, Kao S, Miller WH Jr, Delord JP, Gao B, Planchard D, Gottfried M, et al: Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: Results from the KEYNOTE-028 and KEYNOTE-158 Studies. J Thorac Oncol. 15:618–627. 2020.PubMed/NCBI View Article : Google Scholar
16	Spigel DR, Vicente D, Ciuleanu TE, Gettinger S, Peters S, Horn L, Audigier-Valette C, Pardo Aranda N, Juan-Vidal O, Cheng Y, et al: Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331^*. Ann Oncol. 32:631–641. 2021.PubMed/NCBI View Article : Google Scholar
17	Owonikoko TK, Park K, Govindan R, Ready N, Reck M, Peters S, Dakhil SR, Navarro A, Rodríguez-Cid J, Schenker M, et al: Nivolumab and ipilimumab as maintenance therapy in extensive-disease small-cell lung cancer: CheckMate 451. J Clin Oncol. 39:1349–1359. 2021.PubMed/NCBI View Article : Google Scholar
18	Rudin CM, Awad MM, Navarro A, Gottfried M, Peters S, Csőszi T, Cheema PK, Rodriguez-Abreu D, Wollner M, Yang JC, et al: Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: Randomized, double-blind, phase III KEYNOTE-604 study. J Clin Oncol. 38:2369–2379. 2020.PubMed/NCBI View Article : Google Scholar
19	Yi M, Jiao D, Qin S, Chu Q, Wu K and Li A: Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. Mol Cancer. 18(60)2019.PubMed/NCBI View Article : Google Scholar
20	De Palma M, Biziato D and Petrova TV: Microenvironmental regulation of tumour angiogenesis. Nat Rev Cancer. 17:457–474. 2017.PubMed/NCBI View Article : Google Scholar
21	Sun Y, Niu W, Du F, Du C, Li S, Wang J, Li L, Wang F, Hao Y, Li C and Chi Y: Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors. J Hematol Oncol. 9(105)2016.PubMed/NCBI View Article : Google Scholar
22	Liu Y, Cheng Y, Li K, Shi J, Liu Y, Wu L, Han B, Chen G, He J, Wang J, et al: Effect of prior thoracic radiotherapy on prognosis in relapsed small cell lung cancer patients treated with anlotinib: A subgroup analysis of the ALTER 1202 trial. Transl Lung Cancer Res. 10:3793–3806. 2021.PubMed/NCBI View Article : Google Scholar
23	Wu D, Nie J, Hu W, Dai L, Zhang J, Chen X, Ma X, Tian G, Han J, Han S, et al: A phase II study of anlotinib in 45 patients with relapsed small cell lung cancer. Int J Cancer Dec. 15:3453–3460. 2020.PubMed/NCBI View Article : Google Scholar
24	Nan X, Xie C, Zhu Q, Zhang J, Fu S, Han X, Zhang Q, Han B and Liu J: Hand-foot syndrome and survival in patients with advanced non-small-cell lung cancer receiving anlotinib: A subgroup analysis of data from the ALTER 0303 study. Int J Clin Oncol. 25:1492–1498. 2020.PubMed/NCBI View Article : Google Scholar
25	Mai HQ, Chen QY, Chen D, Hu C, Yang K, Wen J, Li J, Shi YR, Jin F, Xu R, et al: Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: A multicenter randomized phase 3 trial. Nat Med. 27:1536–1543. 2021.PubMed/NCBI View Article : Google Scholar
26	Duan S, Zhang X, Wang F, Shi Y, Wang J and Zeng X: Coexistence of oral mucous membrane pemphigoid and lichenoid drug reaction: A case of toripalimab-triggered and pembrolizumab-aggravated oral adverse events. Oral Surg Oral Med Oral Pathol Oral Radiol. 132:e86–e91. 2021.PubMed/NCBI View Article : Google Scholar